30 research outputs found
The Effect of Age and Recent Influenza Vaccination History on the Immunogenicity and Efficacy of 2009–10 Seasonal Trivalent Inactivated Influenza Vaccination in Children
<div><p>Background</p><p>There is some evidence that annual vaccination of trivalent inactivated influenza vaccine (TIV) may lead to reduced vaccine immunogenicity but evidence is lacking on whether vaccine efficacy is affected by prior vaccination history. The efficacy of one dose of TIV in children 6–8 y of age against influenza B is uncertain. We examined whether immunogenicity and efficacy of influenza vaccination in school-age children varied by age and past vaccination history.</p> <p>Methods and Findings</p><p>We conducted a randomized controlled trial of 2009–10 TIV. Influenza vaccination history in the two preceding years was recorded. Immunogenicity was assessed by comparison of HI titers before and one month after receipt of TIV/placebo. Subjects were followed up for 11 months with symptom diaries, and respiratory specimens were collected during acute respiratory illnesses to permit confirmation of influenza virus infections. We found that previous vaccination was associated with reduced antibody responses to TIV against seasonal A(H1N1) and A(H3N2) particularly in children 9–17 y of age, but increased antibody responses to the same lineage of influenza B virus in children 6–8 y of age. Serological responses to the influenza A vaccine viruses were high regardless of vaccination history. One dose of TIV appeared to be efficacious against confirmed influenza B in children 6–8 y of age regardless of vaccination history.</p> <p>Conclusions</p><p>Prior vaccination was associated with lower antibody titer rises following vaccination against seasonal influenza A vaccine viruses, but higher responses to influenza B among individuals primed with viruses from the same lineage in preceding years. In a year in which influenza B virus predominated, no impact of prior vaccination history was observed on vaccine efficacy against influenza B. The strains that circulated in the year of study did not allow us to study the effect of prior vaccination on vaccine efficacy against influenza A.</p> </div
Factors associated with fatal outcome in 48 MERS cases.
<p>Factors associated with fatal outcome in 48 MERS cases.</p
Factors associated with fatal outcome in 48 MERS cases.
<p>Factors associated with fatal outcome in 48 MERS cases.</p
Individual antibody titers before and one month after receipt of trivalent inactivated influenza vaccine (TIV) in 2009–2010 among 6–8 y (Y, represented by blue circles) and 9–17 y children (O, represented by grey circles) with regard to their vaccination history for the 2007–2008 and 2008–2009 seasons.
<p>The median and interquartile range of antibody titers are shown, p-values were obtained by non parametric Wilcoxon signed rank tests. The comparisons were made with reference to children who were randomized to receive TIV in 2009–10 but did not receive any TIV during 2007–2008 and 2008–2009 seasons. The two p-values shown in each plot were obtained by comparison with children of the same age in the corresponding reference group (6–8 y and 9–17 y).</p
Time from hospital admission to death.
<p>A: Comparing patients with MERS-CoV infection (red line) and those negative for MERS-CoV (black line) (p = 0.01). B: Comparing health care workers with MERS CoV (red dotted line; group1), non-HCW with MERS (red solid line; group 2) and patients without MERS-CoV infection (black solid line; group 3). Log rank test group 1 vs. group 2 p = 0.003; group 2 vs group 3 p = 0.45; group 1 vs group 3 p<0.001.</p
Characteristics of 479 subjects randomized to receive trivalent inactivated influenza vaccine (TIV) in 2009–10 with regard to their vaccination history in 2007–08 and 2008–09.
<p>Characteristics of 479 subjects randomized to receive trivalent inactivated influenza vaccine (TIV) in 2009–10 with regard to their vaccination history in 2007–08 and 2008–09.</p
Viral shedding pattern from observed data for the high, medium or low viral shedding groups.
<p>Viral shedding pattern from observed data for the high, medium or low viral shedding groups.</p
Antigenic relationship between vaccine virus strains included in the trivalent inactivated influenza vaccines for the 2007–2010 seasons (Northern Hemisphere).
<p>Antigenic relationship between vaccine virus strains included in the trivalent inactivated influenza vaccines for the 2007–2010 seasons (Northern Hemisphere).</p
Characteristics of index cases classified as having lower, medium or higher levels of viral shedding at symptom onset, and their household contacts.
<p>Characteristics of index cases classified as having lower, medium or higher levels of viral shedding at symptom onset, and their household contacts.</p
Factors affecting influenza susceptibility and infectivity in the household transmission model.
<p>Factors affecting influenza susceptibility and infectivity in the household transmission model.</p